Clinical Trial Details
— Status: Completed
Administrative data
NCT number |
NCT02600832 |
Other study ID # |
24034 |
Secondary ID |
|
Status |
Completed |
Phase |
N/A
|
First received |
|
Last updated |
|
Start date |
January 2016 |
Est. completion date |
February 7, 2018 |
Study information
Verified date |
December 2018 |
Source |
University of California, San Francisco |
Contact |
n/a |
Is FDA regulated |
No |
Health authority |
|
Study type |
Interventional
|
Clinical Trial Summary
The proposed study is a pilot prospective, parallel groups, randomized, double blind, sham
training-controlled, 9-session (over 3 weeks) clinical trial of AABM in 32 male and female
veterans entering treatment for AUD at the VA Medical Center at San Francisco, California,
between ages 18-65. The study consists of screening, 3-week AABM training, Week-4 post-test,
and Week-12 follow-up. Assessment of inhibitory control, alcohol approach bias and craving
will be administered at baseline and Week-4. Immediately following screening, patients will
be randomly assigned to receive 9 sessions of real or sham AABM training (16 subjects each)
taking place over three weeks. Following the 3 weeks of training, patients will complete a
Week-4 post-test which includes assessment of alcohol approach bias, inhibitory control, and
craving and a Week-12 follow-up assessing drinking behavior.
Description:
The overall goal of the proposed project is to improve the treatment of veterans who consume
alcohol at hazardous or harmful levels. We will conduct a pilot controlled clinical trial to
assess the feasibility and acceptability of implementing an Alcohol Approach Bias
Modification (AABM) task in veterans seeking outpatient treatment for alcohol use disorder
(AUD). The investigators will also explore the efficacy of AABM to reduce alcohol use and
enhance executive function. The proposed study is designed to test AABM as a novel,
acceptable, safe, low-cost intervention to augment and boost the efficacy of standard
outpatient treatment for reducing alcohol use and simultaneously improving executive function
in veterans with AUD.
The proposed project will pursue three primary aims in veterans with an AUD who are drinking
alcohol at hazardous or harmful levels: 1) Establish the feasibility of enrolling and
retaining veterans with AUD for a 3-week randomized trial of AABM; 2) Obtain preliminary
assessment of the efficacy of AABM treatment to decrease alcohol approach bias and alcohol
use; 3) Obtain preliminary assessment of the efficacy of AABM treatment to improve
neurocognitive functioning domains that typically show deficits in AUD populations. To
achieve these aims, we will conduct pilot prospective, parallel groups, randomized, double
blind, sham training-controlled, 9-session (over 3 weeks) clinical trial of AABM in 32 male
and female veterans entering treatment for AUD at the San Francisco VA Medical Center. We
expect that this study will provide empirical data for recruitment, attrition and effect size
estimation for a future randomized trial to definitively test that AABM reduces alcohol use
and improves executive function in veterans with AUD. Moreover, findings from the proposed
project are expected to improve the care of veterans with AUD, and by extension, to aid
families and communities affected by the sequelae of these problems.